Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Pros and Cons for Setting Up “International Center for Regenerative Medicine”: LDP, Komeito Lawmakers
February 27, 2017
- AMED to Deploy “Site Coordinators” to Expedite Drug Discovery
February 24, 2017
- Is “No Gx Substitution” Column in Scripts Still Necessary? Asks Chuikyo Payer Rep
February 23, 2017
- Foreign Price Adjustment Doesn’t Make Much Sense for Drugs with Similar Meds in Japan: Industry
February 23, 2017
- Overhaul Rules to Pick Comparator Meds in Similar Drug Pricing Method: Chuikyo Rep
February 23, 2017
- Council Drafts Scheme to Provide Unapproved Drugs in Response to Infectious Disease Outbreaks in Developing Countries
February 23, 2017
- Use of Generic Drugs Increases, Lingering Concerns Over Quality: Survey
February 23, 2017
- CEFP Working Group to Go Full Throttle on Policy Guidelines Debate in March
February 22, 2017
- New Formats for Package Inserts to Be Announced in April, Enforced from FY2019 with Transition Period: MHLW
February 21, 2017
- MHLW to Strike Balance between Pricing Reform and Generic Promotion: Official
February 20, 2017
- MHLW Advisory Committee to Discuss Ninlaro on March 3
February 20, 2017
- MHLW Advisory Panel to Review Shionogi’s ADHD Drug on March 2
February 17, 2017
- MHLW Ups Ante on Drug Distribution after Fake Harvoni Issue
February 17, 2017
- Council OKs Public Knowledge-Based Applications for Rituxan, Ovisot
February 17, 2017
- MHLW Council Recognizes High Medical Need for 4 APIs/5 Products Including Extended-Release Levodopa/Carbidopa Combo
February 17, 2017
- MHLW Council Discusses Issue of Development Requests for Drugs with Low NHI Prices, Few Patients
February 17, 2017
- With Eye to June Listing, 24 Generic Makers Flock to Micardis Family, 15 to Abilify
February 16, 2017
- Optimal Use Guidelines Issued for Opdivo, Keytruda for Melanoma, NSCLC Use
February 15, 2017
- Label Changes Ordered for Atarax, Zelboraf on New ADRs
February 15, 2017
- MHLW Mulls Administrative Penalties, Tighter Regulations after Counterfeit Harvoni Case
February 14, 2017
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…